Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerDavid D.L. Bowtell, Frances R. Balkwill, Hani Gabra et al.|Nature reviews. Cancer|2015Cited by 1.4k
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseJonathan A. Ledermann, Anna Fagotti, Xavier Matías‐Guiu et al.|Annals of Oncology|2024Cited by 277
Germline Mutation in <i>BRCA1</i> or <i>BRCA2</i> and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian CancerFrancisco José Cândido dos Reis, Honglin Song, Ellen L. Goode et al.|Clinical Cancer Research|2014Cited by 160
Pembrolizumab in Patients With Advanced Clear Cell Gynecological CancerRebecca Kristeleit, Rowan Miller, Michael-John Devlin et al.|JAMA Oncology|2025Cited by 32
Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulationJoaquı́n Mateo, L Rhoda Molife, Michael Friedländer et al.|Unknown|2013Cited by 19